(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 August 2025 (28.08.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/179220 A1

(51) International Patent Classification:
A61P 11/00 (2006.01) *C07K 16/24* (2006.01)
A61P 11/06 (2006.01)

(21) International Application Number:
PCT/US2025/016909

(22) International Filing Date:
21 February 2025 (21.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/556,716	22 February 2024 (22.02.2024)	US
63/690,713	04 September 2024 (04.09.2024)	US
63/743,800	10 January 2025 (10.01.2025)	US
63/752,476	31 January 2025 (31.01.2025)	US

(71) Applicant: **FLAGSHIP PIONEERING INNOVATIONS VI, LLC** [US/US]; 55 Cambridge Parkway, Suite 800E, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **MAYAWALA, Kapil**; 55 Cambridge Parkway, Suite 800E, Cambridge, Massachusetts 02142 (US). **ALIPRANTIS, Antonios O.**; 55 Cambridge Parkway, Suite 800E, Cambridge, Massachusetts 02142 (US). **DENG, Rong**; 55 Cambridge Parkway, Suite 800E, Cambridge, Massachusetts 02142 (US). **DWORAKOWSKI, Wojciech**; 55 Cambridge Parkway, Suite 800E, Cambridge, Massachusetts 02142 (US). **GOYAL, Lovely**; 55 Cambridge Parkway, Suite 800E, Cambridge, Massachusetts 02142 (US). **SZENES, Victoria Zee**; 55 Cambridge Parkway, Suite 800E, Cambridge, Massachusetts 02142 (US).

(74) Agent: **BALICKY, Eric M.** et al.; Hamilton, Brook, Smith & Reynolds, P.C., 55 Old Bedford Rd., Suite 200, Lincoln, Massachusetts 01773 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2025/179220 A1

(54) Title: DOSING OF ANTIGEN BINDING MOLECULES TARGETING THYMIC STROMAL LYMPHOPOIETIN (TSLP)

(57) Abstract: The disclosure provides, in various embodiments, antibodies, antigen-binding fragments thereof, and compositions (e.g., pharmaceutical composition) comprising said antibodies, or antigen-binding fragments thereof, that bind to thymic stromal lymphopoietin (TSLP) and methods for using the same in the treatment of a subject having a TSLP-associated disease or condition.